A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats

[1]  Holly C. Beale,et al.  Whole genome sequencing in cats, identifies new models for blindness in AIPL1 and somite segmentation in HES7 , 2016, BMC Genomics.

[2]  Jian‐Kang Zhu,et al.  De novo assembly and analysis of the transcriptome of Ocimum americanum var. pilosum under cold stress , 2016, BMC Genomics.

[3]  Pu Li,et al.  Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS) , 2016, Clinical Reviews in Allergy & Immunology.

[4]  R. Malik,et al.  COLQ variant associated with Devon Rex and Sphynx feline hereditary myopathy , 2015, Animal genetics.

[5]  K. Thompson,et al.  A Novel and Likely Inherited Lymphoproliferative Disease in British Shorthair Kittens , 2015, Veterinary pathology.

[6]  A. Borkhardt,et al.  A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. , 2014, Clinical immunology.

[7]  Bronwen L. Aken,et al.  Comparative analysis of the domestic cat genome reveals genetic signatures underlying feline biology and domestication , 2014, Proceedings of the National Academy of Sciences.

[8]  G. McVean,et al.  Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.

[9]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[10]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. , 2013, The Journal of allergy and clinical immunology.

[11]  J. B. Oliveira,et al.  How I treat autoimmune lymphoproliferative syndrome. , 2011, Blood.

[12]  F. Rieux-Laucat,et al.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. , 2010, Blood.

[13]  D. Teachey,et al.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) , 2010, British journal of haematology.

[14]  A. Anel,et al.  A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. , 2006, Blood.

[15]  H. Bobby Gaspar,et al.  Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype , 2006, British journal of haematology.

[16]  M. Hentze,et al.  Nonsense-mediated decay approaches the clinic , 2004, Nature Genetics.

[17]  E. Jaffe,et al.  Pathological findings in human autoimmune lymphoproliferative syndrome. , 1998, The American journal of pathology.

[18]  P. Schur,et al.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.

[19]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[20]  J. Inazawa,et al.  Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.

[21]  E. Eicher,et al.  A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice , 1984, The Journal of experimental medicine.

[22]  L. Notarangelo,et al.  Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. , 2016, The Journal of allergy and clinical immunology.

[23]  F Le Deist,et al.  Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways , 2003, Cell Death and Differentiation.

[24]  A. Langerak,et al.  Autoimmune Lymphoproliferative Syndrome (ALPS) in a Child from Consanguineous Parents: A Dominant or Recessive Disease? , 2000, Pediatric Research.

[25]  S. Ju,et al.  Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction. , 1999, International reviews of immunology.

[26]  Heng Li,et al.  BIOINFORMATICS ORIGINAL PAPER , 2022 .

[27]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[28]  Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib. , 2022 .